1
|
Liu X, Wu S, Sun J, Ni S, Lu L, Hu W, Wei H, Zou Y, Li T, Li J, Mijiti B, Fang P, Zhao L, Zhou H, Xing X, Niu H, Cao Y. Changes in clinical trials of endocrine disorder and metabolism and nutrition disorder drugs in mainland China over 2010-2019. Pharmacol Res Perspect 2021; 9:e00729. [PMID: 33660404 PMCID: PMC7931124 DOI: 10.1002/prp2.729] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2020] [Revised: 01/18/2021] [Accepted: 01/19/2021] [Indexed: 01/03/2023] Open
Abstract
With the improvements in relevant policies, laws, and regulations regarding drug clinical trials in China, the quantity and quality of drug clinical trials have gradually improved, and the development prospects of drug clinical trials for endocrine disorders and metabolism and nutrition disorders are promising. Based on information from the clinical trials from the online drug clinical trial registration platform of the National Medical Products Administration, we aimed to review and evaluate the development of clinical trials of drugs for endocrine disorders and metabolism and nutrition disorders in mainland China from 2010 to 2019, as well as the trends over time. A total of 861 trials were carried out on 254 types of drugs for endocrine disorders and metabolism and nutrition disorders, among which 531 (61.67%) involved endocrine disorders, and 330 (38.33%) addressed metabolism and nutrition disorders. The annual number of clinical trials has been increasing gradually, with a significant increase in 2017. Among them, the proportion of clinical trials with Chinese epidemiological characteristics was relatively large (Wu, Annual Report on Development Health Management and Health Industry in China, 2018). The largest number of trials were for diabetes drugs (55.63%), followed by trials of drugs for hyperlipidemia (19.4%) and those for hyperuricemia (7.9%). It was found that the geographical area of the leading units also showed obvious unevenness according to the analysis of the test unit data. Based on the statistics and evaluation of the data, comprehensive information is provided to support the cooperation of global pharmaceutical R&D companies and research units in China and the development of international multicenter clinical trials in China. This work additionally provides clinical trial units with a self‐evaluation of scientific research competitiveness and hospital development strategies. At the same time, it provides a reference with basic data for sponsors and stakeholders in these trials to determine their development strategy goals.
Collapse
Affiliation(s)
- Xin Liu
- School of Pharmacy, Qingdao University, Qingdao, Shandong, China
| | - Suqin Wu
- Phase I Clinical Research Center, The Traditional Chinese Medicine Hospital of Heze, Heze, China
| | - Jian Sun
- Department of Clinical Research, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
| | - Suiqin Ni
- Department of Pharmacy, Guangzhou First People's Hospital, Guangzhou, Guangdong, China
| | - Laichun Lu
- National Institute for Drug Clinical Trial, Beijing Tongren Hospital, Capital Medical University, Beijing, China
| | - Wei Hu
- Department of Clinical Pharmacology, The Second Hospital of Anhui Medical University, Hefei, Anhui, China
| | - Hua Wei
- Department of Pharmacy, Changzheng Hospital, Second Military Medical University, Shanghai, China
| | - Yanqin Zou
- GCP Office, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China
| | - Ting Li
- Clinical Research Unit, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
| | - Jintong Li
- Clinical Trial Center, China-Japan Friendship Hospital, Beijing, China
| | - Bugela Mijiti
- Clinical Research Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China
| | - PingFei Fang
- Phase I Clinical Research Center, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
| | - Limei Zhao
- Phase I Clinical Research Center, The Shengjing Hospital Affiliated China Medical University, Shenyang, Liaoning, China
| | - Huan Zhou
- Phase I Center of Durg Clinical Trial Institution, The Affiliated Hospital of Bengbu Medical College, Bengbu, China
| | - Xiaoming Xing
- Clinical Trials Center, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
| | - Haitao Niu
- Clinical Trials Center, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
| | - Yu Cao
- Clinical Trials Center, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
| |
Collapse
|